· Median time to MRD negatity was 1.7 months (range, 0.9-11.5) 71.4% (10/14 evaluable patients) 72.7% (8/11 evaluable patients) *Presented by YC Cohen at the 22nd International Myeloma Society (IMS) Annual Meeting & Exposition: September 17-20, 2025; Toronto, ON, Canada